Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Larimar Therapeutics Inc (NASDAQ: LRMR) closed at $1.23M in the last session, up 1651579% from day before closing price of $2.74. In other words, the price has increased by $1651579 from its previous closing price. On the day, 1.65 million shares were traded.
Ratios:
We take a closer look at LRMR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.48 and its Current Ratio is at 7.48. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on January 29, 2025, initiated with a Buy rating and assigned the stock a target price of $18.
On October 16, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $26.
On October 03, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $22.Wedbush initiated its Outperform rating on October 03, 2024, with a $22 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LRMR now has a Market Capitalization of 165832256.
Stock Price History:
Over the past 52 weeks, LRMR has reached a high of $11.20, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is 13.46%, while the 200-Day Moving Average is calculated to be -41.15%.
Shares Statistics:
A total of 64.03M shares are outstanding, with a floating share count of 36.46M. Insiders hold about 43.06% of the company’s shares, while institutions hold 62.43% stake in the company.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Larimar Therapeutics Inc (LRMR) involves the perspectives of 6.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.47 and low estimates of -$0.56.
Analysts are recommending an EPS of between -$1.83 and -$2.12 for the fiscal current year, implying an average EPS of -$1.95. EPS for the following year is -$1.75, with 6.0 analysts recommending between -$0.86 and -$2.57.
